11 'Safer' Dividend Dogs Lead 20 May Barron's 2026 Oil And Blue Chips

Barron's Oil & Blue Chip Tips for May 2026 highlight 20 stocks, with 11 deemed 'safer' based on free cash flow yields exceeding dividend yields. Top ten by yield are projected to deliver average net gains of 36.08% by May 2027, with risk/volatility 24% below the market average. Zoetis (ZTS), Danaher (DHR), and Accenture (ACN) lead in projected returns, with ZTS estimated to net 60.33% and lower-than-market volatility.

Seeking Alpha • 11 hours ago

Why Is Danaher (DHR) Down 7% Since Last Earnings Report?

Danaher (DHR) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • May 21, 2026

Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead?

DHR's Biotechnology segment posts 7% core revenue growth as bioprocessing demand stayed strong and equipment orders jumped despite headwinds.

Zacks Investment Research • May 20, 2026

Even a High-Priced Market Has Bargains. 10 Undervalued Blue-Chip Stocks.

Even as tech surges, many other sectors in the market are trading at surprisingly attractive prices.

Barrons • May 15, 2026

Danaher Corporation (DHR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Danaher Corporation (DHR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 13, 2026

Danaher to Present at Bank of America Securities Healthcare Conference

WASHINGTON, May 6, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 13, 2026 at 11:20 a.m.

PRNewsWire • May 6, 2026

Danaher Announces Quarterly Dividend

WASHINGTON, May 5, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 31, 2026 to holders of record on June 26, 2026. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health.

PRNewsWire • May 5, 2026

Masimo Shareholders Approve Acquisition by Danaher

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to adopt the previously announced Agreement and Plan of Merger, dated February 16, 2026 (the “Merger Agreement”), by and among Masimo, Danaher Corporation (“Danaher”) (NYSE: DHR) and Mobius Merger Sub, Inc. (the “Merger Sub”) at Masimo's special meeting of stockholders held virtually on May 1, 2026 (.

Business Wire • May 4, 2026

Danaher reaches $172.5 million settlement with shareholders over post-pandemic outlook

Danaher reached a $172.5 million settlement with shareholders who accused the diagnostics and ​life-sciences company of defrauding them by overstating ‌demand for its equipment as the worst of the COVID-19 pandemic passed.

Reuters • Apr 23, 2026

Danaher Q1 2026 Earnings Update

Danaher had another somewhat uneventful quarter. Margin in biotechnology segment improved YoY to reach 42.7% in 1Q'26. Life Sciences segment's core revenue grew at only 0.5% despite having an easy comp of -4% in 1Q'25.

Seeking Alpha • Apr 22, 2026